FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362606502> ?p ?o ?g. }

• W4362606502 endingPage "e070280" @default.
• W4362606502 startingPage "e070280" @default.
• W4362606502 abstract "Introduction Prostate MRI is a well-established tool for the diagnostic work-up for men with suspected prostate cancer (PCa). Current recommendations advocate the use of multiparametric MRI (mpMRI), which is composed of three sequences: T2-weighted sequence (T2W), diffusion-weighted sequence (DWI) and dynamic contrast-enhanced sequence (DCE). Prior studies suggest that a biparametric MRI (bpMRI) approach, omitting the DCE sequences, may not compromise clinically significant cancer detection, though there are limitations to these studies, and it is not known how this may affect treatment eligibility. A bpMRI approach will reduce scanning time, may be more cost-effective and, at a population level, will allow more men to gain access to an MRI than an mpMRI approach. Methods Prostate Imaging Using MRI±Contrast Enhancement (PRIME) is a prospective, international, multicentre, within-patient diagnostic yield trial assessing whether bpMRI is non-inferior to mpMRI in the diagnosis of clinically significant PCa. Patients will undergo the full mpMRI scan. Radiologists will be blinded to the DCE and will initially report the MRI using only the bpMRI (T2W and DWI) sequences. They will then be unblinded to the DCE sequence and will then re-report the MRI using the mpMRI sequences (T2W, DWI and DCE). Men with suspicious lesions on either bpMRI or mpMRI will undergo prostate biopsy. The main inclusion criteria are men with suspected PCa, with a serum PSA of ≤20 ng/mL and without prior prostate biopsy. The primary outcome is the proportion of men with clinically significant PCa detected (Gleason score ≥3+4 or Gleason grade group ≥2). A sample size of at least 500 patients is required. Key secondary outcomes include the proportion of clinically insignificant PCa detected and treatment decision. Ethics and dissemination Ethical approval was obtained from the National Research Ethics Committee West Midlands, Nottingham (21/WM/0091). Results of this trial will be disseminated through peer-reviewed publications. Participants and relevant patient support groups will be informed about the results of the trial. Trial registration number NCT04571840 ." @default.
• W4362606502 created "2023-04-06" @default.
• W4362606502 creator A5002074685 @default.
• W4362606502 creator A5008343293 @default.
• W4362606502 creator A5012637147 @default.
• W4362606502 creator A5024909099 @default.
• W4362606502 creator A5027424571 @default.
• W4362606502 creator A5032080440 @default.
• W4362606502 creator A5032180724 @default.
• W4362606502 creator A5039146707 @default.
• W4362606502 creator A5046040598 @default.
• W4362606502 creator A5051759845 @default.
• W4362606502 creator A5051970427 @default.
• W4362606502 creator A5055015769 @default.
• W4362606502 creator A5056524769 @default.
• W4362606502 creator A5057813012 @default.
• W4362606502 creator A5073962086 @default.
• W4362606502 creator A5079229552 @default.
• W4362606502 creator A5079529426 @default.
• W4362606502 creator A5083172675 @default.
• W4362606502 creator A5091649890 @default.
• W4362606502 date "2023-04-01" @default.
• W4362606502 modified "2023-10-17" @default.
• W4362606502 title "Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol" @default.
• W4362606502 cites W1827911007 @default.
• W4362606502 cites W2016919721 @default.
• W4362606502 cites W2116116794 @default.
• W4362606502 cites W2171811563 @default.
• W4362606502 cites W2219308129 @default.
• W4362606502 cites W2572332131 @default.
• W4362606502 cites W2612024260 @default.
• W4362606502 cites W2793905111 @default.
• W4362606502 cites W2805452553 @default.
• W4362606502 cites W2900548778 @default.
• W4362606502 cites W2903204344 @default.
• W4362606502 cites W2929897807 @default.
• W4362606502 cites W3039109876 @default.
• W4362606502 cites W4220770752 @default.
• W4362606502 doi "https://doi.org/10.1136/bmjopen-2022-070280" @default.
• W4362606502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37019486" @default.
• W4362606502 hasPublicationYear "2023" @default.
• W4362606502 type Work @default.
• W4362606502 citedByCount "6" @default.
• W4362606502 countsByYear W43626065022023 @default.
• W4362606502 crossrefType "journal-article" @default.
• W4362606502 hasAuthorship W4362606502A5002074685 @default.
• W4362606502 hasAuthorship W4362606502A5008343293 @default.
• W4362606502 hasAuthorship W4362606502A5012637147 @default.
• W4362606502 hasAuthorship W4362606502A5024909099 @default.
• W4362606502 hasAuthorship W4362606502A5027424571 @default.
• W4362606502 hasAuthorship W4362606502A5032080440 @default.
• W4362606502 hasAuthorship W4362606502A5032180724 @default.
• W4362606502 hasAuthorship W4362606502A5039146707 @default.
• W4362606502 hasAuthorship W4362606502A5046040598 @default.
• W4362606502 hasAuthorship W4362606502A5051759845 @default.
• W4362606502 hasAuthorship W4362606502A5051970427 @default.
• W4362606502 hasAuthorship W4362606502A5055015769 @default.
• W4362606502 hasAuthorship W4362606502A5056524769 @default.
• W4362606502 hasAuthorship W4362606502A5057813012 @default.
• W4362606502 hasAuthorship W4362606502A5073962086 @default.
• W4362606502 hasAuthorship W4362606502A5079229552 @default.
• W4362606502 hasAuthorship W4362606502A5079529426 @default.
• W4362606502 hasAuthorship W4362606502A5083172675 @default.
• W4362606502 hasAuthorship W4362606502A5091649890 @default.
• W4362606502 hasBestOaLocation W43626065021 @default.
• W4362606502 hasConcept C121608353 @default.
• W4362606502 hasConcept C126322002 @default.
• W4362606502 hasConcept C126838900 @default.
• W4362606502 hasConcept C141071460 @default.
• W4362606502 hasConcept C142724271 @default.
• W4362606502 hasConcept C188816634 @default.
• W4362606502 hasConcept C2775934546 @default.
• W4362606502 hasConcept C2776235491 @default.
• W4362606502 hasConcept C2780192828 @default.
• W4362606502 hasConcept C2910607126 @default.
• W4362606502 hasConcept C535046627 @default.
• W4362606502 hasConcept C71924100 @default.
• W4362606502 hasConceptScore W4362606502C121608353 @default.
• W4362606502 hasConceptScore W4362606502C126322002 @default.
• W4362606502 hasConceptScore W4362606502C126838900 @default.
• W4362606502 hasConceptScore W4362606502C141071460 @default.
• W4362606502 hasConceptScore W4362606502C142724271 @default.
• W4362606502 hasConceptScore W4362606502C188816634 @default.
• W4362606502 hasConceptScore W4362606502C2775934546 @default.
• W4362606502 hasConceptScore W4362606502C2776235491 @default.
• W4362606502 hasConceptScore W4362606502C2780192828 @default.
• W4362606502 hasConceptScore W4362606502C2910607126 @default.
• W4362606502 hasConceptScore W4362606502C535046627 @default.
• W4362606502 hasConceptScore W4362606502C71924100 @default.
• W4362606502 hasFunder F4320320292 @default.
• W4362606502 hasFunder F4320330875 @default.
• W4362606502 hasFunder F4320331450 @default.
• W4362606502 hasIssue "4" @default.
• W4362606502 hasLocation W43626065021 @default.
• W4362606502 hasLocation W43626065022 @default.
• W4362606502 hasLocation W43626065023 @default.
• W4362606502 hasLocation W43626065024 @default.
• W4362606502 hasLocation W43626065025 @default.

• next